B. Riley Securities Reiterates Buy on Anika Therapeutics, Lowers Price Target to $17

Benzinga · 3d ago
B. Riley Securities analyst Madison El-Saadi reiterates Anika Therapeutics (NASDAQ:ANIK) with a Buy and lowers the price target from $23 to $17.